SunRock Biopharma
Business Services · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sionlla Cesieb L1 Biopolo 3, Santiago de...Phone Number
+34 881975523Website
www.sunrockbiopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About SunRock Biopharma
SunRock Biopharma is a biotech company focused on developing antibodies for highly invasive tumors in oncology. The company transforms academic research into immunotherapy solutions, collaborating with a network of experts to address complex, currently untreatable pathologies. SunRock's pipeline includes innovative programs targeting CCR9 and HER3, which are associated with tumor progression and resistance to conventional treatments. Their novel antibodies demonstrate improved efficacy and safety in preclinical models, aiming to enhance cancer therapy outcomes.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SunRock Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SunRock Biopharma had a recent Job posting/layoffs
Check out if SunRock Biopharma is spiking on competitors!
Earning: See what the market has to say on SunRock Biopharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SunRock Biopharma
Product Launch: Get notified when SunRock Biopharma launches new products
SunRock Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SunRock Biopharma has new funding data
Check if SunRock Biopharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
SunRock Biopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SunRock Biopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SunRock Biopharma.
SunRock Biopharma Tech Stack
A closer look at the technologies used by SunRock Biopharma
See more technologies
SunRock Biopharma News & Media
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
LAUSANNE, Switzerland & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced an exclusive option and license agreement with SunRock Biopharma (www.sunrockbiopharma.com), a Galician company supported by the regional government, Xunta de Galicia, through Xesgalicia, devoted to the development of antibodies agaEllipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein
LONDON & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)--SunRock Biopharma S.L. (“SunRock”), a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, whichSunRock Biopharma and GenScript ProBio Enter into a Collaboration Agreement to Develop Novel Monoclonal Antibody Program
NANJING, China, Feb. 22, 2021 /PRNewswire/ -- On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock's CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug pro
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding SunRock Biopharma
Sign Up For FreeTo access detailed company insights
SunRock Biopharma is a biotech company focused on developing antibodies for highly invasive tumors in oncology. The company transforms academic research into immunotherapy solutions, collaborating with a network of experts to address complex, currently untreatable pathologies. SunRock's pipeline includes innovative programs targeting CCR9 and HER3,... Read More
